Representative Ritchie Torres (D-New York) recently sold shares of AbbVie Inc. NYSE: ABBV. In a filing disclosed on August 20th, the Representative disclosed that they had sold between $1,001 and $15,000 in AbbVie stock on July 11th.
Representative Ritchie Torres also recently made the following trade(s):
- Sold $1,001 - $15,000 in shares of Equity Lifestyle Properties NYSE: ELS on 7/11/2025.
- Sold $1,001 - $15,000 in shares of Northrop Grumman NYSE: NOC on 7/11/2025.
- Sold $1,001 - $15,000 in shares of Emerson Electric NYSE: EMR on 7/11/2025.
- Sold $1,001 - $15,000 in shares of Kinder Morgan NYSE: KMI on 7/11/2025.
- Sold $1,001 - $15,000 in shares of MetLife NYSE: MET on 7/11/2025.
- Sold $1,001 - $15,000 in shares of Oracle NYSE: ORCL on 7/11/2025.
- Sold $1,001 - $15,000 in shares of Equity Residential NYSE: EQR on 7/11/2025.
- Sold $1,001 - $15,000 in shares of McKesson NYSE: MCK on 7/11/2025.
- Sold $1,001 - $15,000 in shares of Ares Management NYSE: ARES on 7/11/2025.
- Sold $1,001 - $15,000 in shares of Otis Worldwide NYSE: OTIS on 7/11/2025.
AbbVie Trading Up 0.4%
Shares of AbbVie stock traded up $0.7840 on Friday, hitting $210.2840. The stock had a trading volume of 4,818,093 shares, compared to its average volume of 6,663,225. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a one year low of $163.81 and a one year high of $218.66. The stock's 50-day simple moving average is $192.45 and its two-hundred day simple moving average is $192.81. The stock has a market cap of $371.48 billion, a price-to-earnings ratio of 100.14, a PEG ratio of 1.34 and a beta of 0.50.
AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported $2.97 EPS for the quarter, missing analysts' consensus estimates of $3.24 by ($0.27). The firm had revenue of $15.42 billion for the quarter, compared to the consensus estimate of $14.93 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.65 earnings per share. As a group, sell-side analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.
AbbVie Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th were issued a $1.64 dividend. The ex-dividend date was Tuesday, July 15th. This represents a $6.56 annualized dividend and a dividend yield of 3.1%. AbbVie's dividend payout ratio (DPR) is currently 312.38%.
Wall Street Analysts Forecast Growth
ABBV has been the subject of a number of analyst reports. Daiwa Capital Markets upgraded shares of AbbVie from a "neutral" rating to an "outperform" rating and set a $214.00 target price for the company in a report on Thursday, August 7th. Evercore ISI upped their price target on AbbVie from $204.00 to $205.00 and gave the company an "outperform" rating in a research report on Monday, April 28th. Citigroup increased their price objective on AbbVie to $205.00 and gave the stock a "hold" rating in a report on Wednesday, June 11th. Wall Street Zen cut AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. Finally, BNP Paribas upgraded AbbVie to a "hold" rating in a report on Thursday, May 8th. Five analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $214.95.
Read Our Latest Research Report on ABBV
Insider Activity
In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the transaction, the executive vice president directly owned 177,292 shares of the company's stock, valued at approximately $35,178,278.64. This represents a 19.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Nicholas Donoghoe sold 13,295 shares of the stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the sale, the executive vice president owned 58,247 shares in the company, valued at approximately $11,562,611.97. This represents a 18.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.25% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the business. Brighton Jones LLC grew its stake in shares of AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company's stock worth $4,072,000 after acquiring an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC boosted its stake in AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company's stock worth $1,294,000 after purchasing an additional 3,064 shares in the last quarter. TD Waterhouse Canada Inc. boosted its stake in AbbVie by 8.0% in the 4th quarter. TD Waterhouse Canada Inc. now owns 55,598 shares of the company's stock worth $9,885,000 after purchasing an additional 4,133 shares in the last quarter. J. Safra Sarasin Holding AG grew its position in AbbVie by 99.1% during the 4th quarter. J. Safra Sarasin Holding AG now owns 39,913 shares of the company's stock valued at $7,081,000 after purchasing an additional 19,863 shares during the last quarter. Finally, Steel Grove Capital Advisors LLC increased its stake in AbbVie by 1.7% during the 4th quarter. Steel Grove Capital Advisors LLC now owns 3,110 shares of the company's stock valued at $553,000 after purchasing an additional 52 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.
About Representative Torres
Ritchie Torres (Democratic Party) is a member of the U.S. House, representing New York's 15th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027.
Torres (Democratic Party) ran for re-election to the U.S. House to represent New York's 15th Congressional District. He won in the general election on November 5, 2024.
Ritchie Torres lives in the Bronx, New York.
AbbVie Company Profile
(
Get Free Report)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
MarketBeat All Access